# EDGAR Filing Document

**Accession Number:** 0001674416
**File Stem:** 0000950170-23-010439
**Filing Date:** 2023-3
**Character Count:** 8539
**Document Hash:** b0d67538acb91ffd34e14001e1547c66
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-010439.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0000950170-23-010439

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230328

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CRISPR Therapeutics AG
- **CENTRAL INDEX KEY:** 0001674416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 473173478
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37923
- **FILM NUMBER:** 23771825

**BUSINESS ADDRESS:**
- **STREET 1:** BAARERSTRASSE 14
- **CITY:** ZUG
- **STATE:** V8
- **ZIP:** CH-6300
- **BUSINESS PHONE:** 6173154600

**MAIL ADDRESS:**
- **STREET 1:** BAARERSTRASSE 14
- **CITY:** ZUG
- **STATE:** V8
- **ZIP:** CH-6300

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** March 28, 2023<br>

------

CRISPR THERAPEUTICS AG

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Switzerland | 001-37923 | Not Applicable |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| Baarerstrasse 14 |  |  |
| 6300 Zug**,** Switzerland |  | **Not Applicable** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 41 (0)41 561 32 77<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Shares, nominal value CHF 0.03 | CRSP | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the "Company") of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023. Dr. Bolzon's resignation was not the result of any dispute or disagreement with the Company or the Company's Board of Directors on any matter relating to the operations, policies or practices of the Company.

The full text of the press release announcing Dr. Bolzon's resignation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**Item 9.01 Financial Statements and Exhibits.**

(d) <u>Exhibits</u>:

The following exhibits shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| **Exhibit<br>No.** | <br>**Description** |
| 99.1 | [<u>Press Release by CRISPR Therapeutics AG, dated March 29, 2023</u>](crsp-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | CRISPR Therapeutics AG |
| Date: | March 29, 2023 | By:  | /s/ Samarth Kulkarni |
|  |  |  | Samarth Kulkarni, Ph.D.<br>Chief Executive Officer |

---

------

## Ex-99

**Exhibit 99.1**

**CRISPR Therapeutics Announces Departure of Board Member**

**ZUG, Switzerland and Boston, Mass., March 29, 2023** -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.

"From the very beginning, Brad has been instrumental in defining the vision and strategy for CRISPR Therapeutics and has guided the company through many stages of development," said Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics. "It has been a pleasure working with him and I would personally like to thank Brad for his ongoing support."

"Brad has made immeasurable contributions to the company since its founding and has been a driving force behind the company's success," said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. "His extensive experience and strategic insights have been critical in establishing CRISPR Therapeutics as a pre-eminent gene editing company, and more importantly, in bringing life-saving medicines to patients. I am personally grateful for his counsel, and on behalf of our Board of Directors and the management team, I would like to thank him for his years of service on the Board."

"I am very proud of this leadership team's many accomplishments over the past decade," said Dr. Bolzon. "CRISPR Therapeutics exemplifies what life science venture capitalists strive for -- generating significant value for all shareholders and, most importantly, pioneering the next generation of medicines to help those patients most in need. I wish management and the board further success on this journey and have the utmost confidence that they will continue to execute at the highest level."

**About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

**Investor Contact:**

Susan Kim

+1-617-315-4600

susan.kim@crisprtx.com

**Media Contact:**

Rachel Eides

------

+1-617-315-4493

rachel.eides@crisprtx.com

------